LivaNova heads into the final stretch of summer with an unusual split: short interest climbing at its fastest pace in months, while options traders have swung to their most bullish posture in over a year.
The short positioning tells a more pointed story than the stock's quiet price action suggests. Short interest has risen 13.6% in one week and 18.8% over the past month, reaching 8.6% of free float — the highest level since at least mid-July. In absolute terms, roughly 4.7 million shares are now sold short. The move is notable because it happened in a single step: short interest jumped sharply around August 24-25, from roughly 4.2 million shares to 4.7 million, and has held near that elevated level since. Despite the rebuild, the borrow market remains wide open. Availability runs at 825% — meaning there are roughly eight shares available to lend for every one already borrowed — and cost to borrow is a negligible 0.5%. There is no squeeze dynamic here; the lending pool is deep and the borrow is cheap.
Options positioning tells the opposite story. The put/call ratio has dropped to 0.46, nearly 1.4 standard deviations below its 20-day average of 0.68, and is closer to the 52-week low of 0.07 than the high of 0.88. That kind of call-heavy skew points to meaningful demand for upside exposure. The shift is stark in the history: the PCR ran above 0.80 for the entire first half of August, then snapped lower around August 24 — precisely when short interest jumped. Two camps forming at the same moment is the week's central tension.
The Street is broadly constructive on the stock. Piper Sandler reiterated Overweight and lifted its price target to $90 on September 2, adding to a string of upward revisions that has pushed the consensus target to $89.10, against a current price of $80.16. That implies roughly 11% upside to consensus. Needham raised its target to $93 after the August earnings print; Mizuho's Outperform carries a $95 target. The outlier is Barclays, which holds an Equal-Weight at $76 — effectively a ceiling call — while Baird trimmed its target in May though kept Outperform. The bull case centres on the aura6000 device, where estimates run from $120 million in 2027 to $280 million by 2029 under favourable conditions, and management's full-year revenue guidance of $940-955 million. Bears point to the August earnings print, where LivaNova fell 11.2% on the day and a further 5.3% over the following week — a reminder that execution risk remains real heading into the October 28 result. Valuation is not stretched: the stock trades at 17.5x trailing earnings and 11.7x EV/EBITDA, and both multiples have been broadly stable over the past month.
Institutional ownership adds a constructive undertone. BlackRock is the largest holder at 13.7% of shares, and recently reported adding 426,000 shares. FMR (Fidelity) filed a fresh Schedule 13G in August disclosing a 5.8% stake — a new position crossing the 5% threshold. Hood River Capital added nearly 1.9 million shares in the quarter ending June 30, making it the fourth-largest holder. No 13D activist is on the register, and the insider data is too stale (last filed December 2025) to draw conclusions about recent management conviction. The disclosure caveat applies: all 13D/G positions are as-last-reported around the 5% threshold and can change without an immediate filing.
Peer context offers mild reassurance. Most correlated names had a tougher week — SYK fell 4% and COO dropped 5.1% — while LIVN closed up 0.9%. The sharp exception is ENOV, off 19.7% on the week, a reminder that single-name risk in med-tech remains elevated. What to watch next is the October 28 earnings date: given the stock's 11% drop last quarter, the gap between a call-heavy options market and a growing short book will likely narrow — or widen sharply — around that event.
See the live data behind this article on ORTEX.
Open LIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
